Microfluidic qPCR Chamber Replacement for Defect Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid amplification methods, such as qPCR, face issues with quantitative and qualitative defects in starting materials, leading to inadequate fluorescence intensity and incorrect DNA fragment detection.
Innovation Solution
A microfluidic device with a cartridge system that includes a control part to manage thermal cycles, detect fluorescence intensity, and replace defective chambers with new solution, utilizing heaters, temperature sensors, and flow paths to improve temperature control and solution exchange.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qPCR is performed with starting material containing defective DNA fragments, then the fluorescence intensity is weakened and the desired result cannot be obtained, but the process continues without detection until the defect is revealed
Solution Approach 1:
The patent applies preliminary action by performing a pre-amplification step before the main qPCR process. This preliminary amplification allows defective chambers to be identified and replaced before the critical measurement phase, preventing defective starting materials from compromising the final results. The system counts the number of amplification cycles performed and monitors fluorescence intensity at each step to detect defects early.
Solution Approach 2:
The patent implements feedback by continuously monitoring fluorescence intensity during the thermal cycling process and comparing it against expected values. When the fluorescence intensity deviates from the predetermined range or the amplification curve does not follow the expected pattern, the system identifies the chamber as defective and triggers a replacement action. This feedback mechanism ensures that only chambers with proper starting materials proceed to the final measurement phase.
2Measurement precision
If the thermal cycle time is extended to ensure complete amplification, then the DNA fragment detection accuracy improves, but the total processing time increases
Solution Approach 1:
The patent performs preliminary amplification in a separate step before the main qPCR process. This preliminary action allows the system to identify and replace defective chambers early, so that the main amplification can proceed with confidence that the starting materials are correct. This separation enables optimized timing where defective chambers are handled quickly while proper chambers undergo the full amplification protocol.
Solution Approach 2:
The patent applies the skipping principle by rapidly identifying and replacing defective chambers during the amplification process. When a chamber is detected as defective through fluorescence monitoring, the system skips the remaining amplification cycles for that chamber and replaces it with a new sample, rather than continuing to waste time on a failed reaction. This allows the overall process to recover time by eliminating futile amplification steps.
3Productivity
If multiple first chambers are used to process multiple samples simultaneously, then the productivity increases, but the probability of having defective chambers increases
Solution Approach 1:
The patent divides the sample processing into multiple independent first chambers, each capable of being individually monitored and replaced. This segmentation allows parallel processing of multiple samples while maintaining the ability to identify and handle defective chambers independently. Each chamber is assigned a unique identifier and can be managed separately by the control unit, enabling high throughput while preserving quality control.
Solution Approach 2:
The patent implements individual feedback monitoring for each first chamber by tracking the fluorescence intensity and amplification progress of each chamber separately. When a chamber is detected as defective, the feedback mechanism triggers replacement only for that specific chamber while other chambers continue processing uninterrupted. This selective feedback approach maintains high productivity by minimizing the impact of defects on the overall batch.
4Reliability
If the solution is discharged and replaced in defective chambers during the process, then the adverse effects from defective starting materials are reduced, but the device complexity increases
Solution Approach 1:
The patent uses segmented, modular first chambers that can be individually accessed and replaced. Each chamber is designed as an independent unit with standardized interfaces for solution loading and discharge. This modular segmentation simplifies the replacement mechanism compared to attempting to repair or clean entire amplification systems, as only the affected chamber needs to be handled.
Solution Approach 2:
The patent implements self-service through automated detection and replacement mechanisms. The control unit automatically monitors fluorescence intensity, identifies defective chambers, and triggers the discharge and replacement of solution without requiring manual intervention for each defect. The system uses the existing thermal cycling and fluorescence detection infrastructure to automatically manage quality control, reducing the need for additional complex external monitoring equipment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device reduces adverse effects from defective starting materials by identifying and replacing flawed chambers, enhancing temperature control and solution processing efficiency, thereby improving DNA amplification accuracy and reducing cycle time.
Implementation Method 1
a heater 24 corresponding to each first chamber 21; in the thermal cycle, the time required for heating the first chamber (21) to the target temperature can be shortened
Implementation Method 2
a temperature sensor (25) corresponding to each first chamber (21)
Implementation Method 3
a light source (5) irradiating light to the first chamber (21)
Implementation Method 4
a light receiving sensor (6) measuring a fluorescence intensity of the first chamber (21)
Data Source
AI summary
A microfluidic device for amplifying a nucleic acid includes a cartridge and a control part. The cartridge includes a tank part and a plurality of first chambers. The control part is configured to control execution of a thermal cycle, count a number of repetitions of the thermal cycle for each of the first chambers and store a count value, acquire a fluorescence intensity of each of the first chambers for each thermal cycle, and reset the count value of a defective chamber of which the fluorescence intensity is not within a predetermined range, discharge the solution from the defective chamber, and fill the defective chamber with a new solution from the tank part.